265 reports of this reaction
2.0% of all CLADRIBINE reports
#11 most reported adverse reaction
URINARY TRACT INFECTION is the #11 most commonly reported adverse reaction for CLADRIBINE, manufactured by EMD Serono, Inc.. There are 265 FDA adverse event reports linking CLADRIBINE to URINARY TRACT INFECTION. This represents approximately 2.0% of all 13,464 adverse event reports for this drug.
Patients taking CLADRIBINE who experience urinary tract infection should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
URINARY TRACT INFECTION is a less commonly reported adverse event for CLADRIBINE, but still significant enough to appear in the safety profile.
In addition to urinary tract infection, the following adverse reactions have been reported for CLADRIBINE:
The following drugs have also been linked to urinary tract infection in FDA adverse event reports:
URINARY TRACT INFECTION has been reported as an adverse event in 265 FDA reports for CLADRIBINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
URINARY TRACT INFECTION accounts for approximately 2.0% of all adverse event reports for CLADRIBINE, making it a notable side effect.
If you experience urinary tract infection while taking CLADRIBINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.